openPR Logo
Press release

Investigation for Investors in NASDAQ: BGNE shares over possible Wrongdoing at BeiGene, Ltd.

03-19-2020 06:39 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in BeiGene, Ltd. (NASDAQ: BGNE) shares over potential wrongdoing at BeiGene, Ltd.

An investigation on behalf of investors in BeiGene, Ltd. (NASDAQ: BGNE) shares over potential wrongdoing at BeiGene, Ltd.

An investigation on behalf of current long-term investors in shares of BeiGene, Ltd. (NASDAQ: BGNE) was announced over potential breaches of fiduciary duties by certain officers and directors at BeiGene, Ltd.

Investors who purchased shares of BeiGene, Ltd. (NASDAQ: BGNE) and currently hold any of those NASDAQ: BGNE shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain BeiGene, Ltd. directors breached their fiduciary duties and caused damage to the company and its shareholders.

China based BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationaly.

On September 5, 2019, a report was published concerning BeiGene, Ltd. The report asserted, inter alia, that BeiGene "is faking sales in order to persuade investors that it can develop a successful platform in China" and that "management may also be skimming R&D and capital budgets."

Shares of BeiGene, Ltd. (NASDAQ: BGNE) declined to as low as $118.00 per share on September 6, 2019.

Those who purchased shares of BeiGene, Ltd. (NASDAQ: BGNE) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Investors in NASDAQ: BGNE shares over possible Wrongdoing at BeiGene, Ltd. here

News-ID: 1976300 • Views: 266

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Qurate Retail, Inc. (NASDAQ: …
Qurate Retail, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Qurate Retail, Inc. (NASDAQ: QRTEA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Qurate Retail, Inc. regarding its business, its prospects and its operations were materially false
Lawsuit filed for Investors in shares of Allakos Inc. (NASDAQ: ALLK)
An investor, who purchased shares of Allakos Inc. (NASDAQ: ALLK), filed a lawsuit over alleged Securities Laws violations by Allakos Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Allakos Inc. (NASDAQ: ALLK) have certain options and for certain investors are short and strict deadlines running. Deadline: May 11, 2020. NASDAQ: ALLK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Investors in NASDAQ:LNDC shares over potential Wrong …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors at Landec Corporation. Investors who purchased shares of Landec Corporation (NASDAQ: LNDC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Landec directors breached their fiduciary duties and caused damage to the company and its shareholders. Santa Clara, CA based Landec Corporation, together
Lawsuit filed for Investors in shares of PaySign, Inc. (NASDAQ: PAYS)
An investor, who purchased shares of PaySign, Inc. (NASDAQ: PAYS), filed a lawsuit over alleged Securities Laws violations by PaySign, Inc. Investors in shares of PaySign, Inc. (NASDAQ: PAYS) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 9, 2019, PaySign, Inc lowered its fiscal 2019 revenue guidance to a range of $35 million to $37 million, from prior guidance range of $38 million to $40

All 5 Releases


More Releases for BeiGene

Targeted Drug BRAF Inhibitors for NSCLC Market 2019-2024 Analysis Reports Revenu …
According to study, over the next five years the Targeted Drug BRAF Inhibitors for NSCLC market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Targeted Drug BRAF Inhibitors for NSCLC business. This report presents a comprehensive overview, market
Global Gallbladder Cancer Treatment Market Report 2019-2025| 4SC AG, Advenchen L …
UpMarketResearch offers a latest published report on “Global Gallbladder Cancer Treatment Market Industry Analysis and Forecast 2019-2025” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 125 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. The report contains basic, secondary and advanced information pertaining to the Gallbladder Cancer Treatment global
Biomarkers and Companion Diagnostics in Oncology 2019| Abbott Molecular, Amoy Di …
Albany, NY, 30th January : Recent research and the current scenario as well as future market potential of "Biomarkers and Companion Diagnostics in Oncology" globally. A biomarker is a defined molecular characteristic, for example a genetic mutation, that can tell a physician more about a patients disease state, or how they might respond to treatment. Predictive biomarkers indicate how likely a patient is to respond to a treatment, and are used
Global Diffuse Large B Cell Lymphoma Drug Market 2018 - AbbVie, BeiGene, Celltri …
Apex Market Reports, recently published a detailed market research study focused on the “Diffuse Large B Cell Lymphoma Drug Market” across the global, regional and country level. The report provides 360° analysis of “Diffuse Large B Cell Lymphoma Drug Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and
Fibrosarcoma - Pipeline by BeiGene Ltd, Cell Medica Ltd, Eli Lilly and Co, and K …
Fibrosarcoma Overview                 Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes. Click here for sample report @ https://www.wiseguyreports.com/sample-request/3010392-fibrosarcoma-pipeline-review-h1-2018   Major Key Players: AntiCancer Inc Cellestia Biotech AG Elsalys Biotech SAS Ignyta Inc Intezyne Technologies Inc Loxo Oncology Inc Fibrosarcoma Industry Major Outlook Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma    - Pipeline Review, H1 2018, provides comprehensive information on the
Poly (ADP-ribose) Market Global Key Players – AbbVie Inc, BeiGene Ltd, Clovis …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Poly (ADP-ribose) - Pipeline Review, H2 2017” Poly (ADP-ribose) Overview Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by